Please sign in to follow a disease.
Hyperimmunoglobulin syndrome
MONDO:0002468Also known as: hyperimmunoglobulin syndrome
74 clinical trials for this condition and its sub-types, 0 tagged with Hyperimmunoglobulin syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Hyperimmunoglobulin syndrome
-
Hyper-IgE syndrome 5 trials · 26 incl. sub-types
14 sub-types
- Netherton syndrome 16 trials
- Combined immunodeficiency due to DOCK8 deficiency 6 trials
- Hyper-IgE recurrent infection syndrome 1, autosomal dominant 3 trials
- Autosomal dominant combined immunodeficiency due to ERBIN deficiency 0 trials
- Autosomal dominant combined immunodeficiency due to partial IL6ST deficiency 0 trials
- Autosomal recessive combined immunodeficiency due to IL6R deficiency 0 trials
- Autosomal recessive combined immunodeficiency due to complete IL6ST deficiency 0 trials
- Autosomal recessive combined immunodeficiency due to partial IL6ST deficiency 0 trials
- Hyper-IgE recurrent infection syndrome 3, autosomal recessive 0 trials
- Hyper-IgE recurrent infection syndrome 4, autosomal recessive 0 trials
- Hyper-IgE recurrent infection syndrome 4A, autosomal dominant 0 trials
- Hyper-IgE recurrent infection syndrome 5, autosomal recessive 0 trials
- Hyper-IgE syndrome 6, autosomal dominant, with recurrent infections 0 trials
- Immunodeficiency 94 with autoinflammation and dysmorphic facies 0 trials
-
Hyper-IgM syndrome 8 trials · 9 incl. sub-types
5 sub-types
- Hyper-IgM syndrome type 1 3 trials
- Hyper-IgM syndrome type 2 1 trial
- Hyper-IgM syndrome type 3 1 trial
- Hyper-IgM syndrome type 5 1 trial
- Hyper-IgM syndrome type 4 0 trials
-
Experimental drug for rare skin disease fails to reach goal
Disease control Stopped earlyThis early-stage trial tested a drug called DS-2325a in 9 adults with Netherton syndrome, a rare genetic condition causing severe skin redness, scaling, and allergies. The study aimed to check safety and whether the drug could help control the disease. However, the trial was term…
Phase 1/2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Hope for rare skin disease: new drug shows promise in trial
Disease control Stopped earlyThis study tested a medicine called spesolimab for people with Netherton syndrome, a rare genetic skin condition causing severe redness and scaling. About 43 people aged 12 and older took part, receiving either the drug or a placebo. The goal was to see if spesolimab could reduce…
Phase 2/3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can an eczema drug calm a rare genetic skin disease?
Symptom relief Stopped earlyNetherton syndrome is a rare genetic disorder that causes red, scaly, inflamed skin and intense itching. No targeted treatments exist, so researchers are testing dupilumab, an injectable drug already used for eczema, against a placebo in 10 adults with moderate to severe Netherto…
Phase 2/3 • Sponsor: University Hospital, Toulouse • Aim: Symptom relief
Last updated Sep 21, 2026 21:00 UTC
-
Rare skin disease study seeks to understand netherton syndrome
Knowledge-focused Stopped earlyThis study aimed to collect real-world data on Netherton Syndrome, a rare genetic skin disorder. Researchers planned to follow 4 participants over 52 weeks, measuring skin severity and other symptoms. The study was terminated early, so results are limited.
Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC